Acadia Pharmaceuticals Inc. ACAD

Health CareBiotechnology & Medical ResearchUnited States of America

Last close 20.47 USD on Nov 2, 2026, −23.4% year to date

Quant rating

Quant rating A Rank 61 of 565 in Health Care

Growth C 264 of 565
Valuation A 37 of 565
Quality A 3 of 565
Revisions A 68 of 565
Momentum D 399 of 565

Wall Street consensus Buy (2.05)Average target 30.42 USD +48.6%

Historical valuation

Multiples use consensus estimates for the next twelve months. The dashed line is the 5-year average.

Key data

Market cap: 3.5B
Enterprise value: 2.6B
52-week range: 18.40 – 30.95
3-year range: 14.10 – 31.77
Dividend yield: –
Beta (5 years): 0.89
Shares outstanding: 172M
Next earnings: Nov 4, 2026

About the company

Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.

Growth and profitability fiscal year ends December 31

Growth and profitability by fiscal year
	2025	2024	2023	2022	2021	5Y avg
Revenue (mil)	1,072	958	726	517	484	–
Revenue growth	11.9%	31.8%	40.4%	6.8%	9.6%	19.4%
EPS (basic, normalized)	2.30	0.48	−0.37	−1.34	−1.05	–
EPS growth	379.2%	–	–	–	–	–
Gross margin	91.7%	91.5%	94.3%	98.0%	96.3%	94.3%
Net margin	36.5%	23.6%	−8.4%	−41.8%	−34.7%	−4.9%
ROE	39.9%	38.9%	−14.7%	−45.9%	−28.7%	−2.1%

Balance sheet, last quarter
Cash & short-term investments (mil)	956
Current ratio	3.39x
Long-term debt (mil)	0
Net debt (mil)	−956
Total equity (mil)	1,307
Net debt / equity	−0.73x
Net debt / EBITDA	−8.20x

Estimates and valuation

Consensus estimates and implied multiples
	Sales (mil)			EBITDA (mil)			EPS
Fiscal year	Mean est.	Growth	EV/Sales	Mean est.	Growth	EV/EBITDA	Mean est.	Growth	P/E
2025 actual	1,072	+11.9%	2.4x	117	−0.9%	22.0x	2.30	+379.2%	8.9x
2026	1,272	+18.8%	2.0x	123	+5.3%	20.9x	0.62	−72.9%	32.9x
2027	1,433	+12.6%	1.8x	189	+53.6%	13.6x	0.93	+49.2%	22.0x
2028	1,610	+12.3%	1.6x	354	+87.6%	7.3x	1.55	+66.7%	13.2x

Estimate revisions

Change in consensus estimates over 1, 3 and 6 months
	Sales				EPS
Fiscal year	Estimate (mil)	1M	3M	6M	Estimate	1M	3M	6M
2026	1,272	0.0%	+1.4%	+2.3%	0.62	+1.2%	+20.9%	+40.5%
2027	1,433	0.0%	+1.1%	+3.1%	0.93	+0.4%	+0.5%	−1.5%
2028	1,610	0.0%	+0.4%	+2.7%	1.55	+0.5%	−0.1%	−1.9%

Earnings surprises EPS beat in 3 of the last 4 quarters

Reported results versus consensus, last 10 fiscal quarters
Quarter ended	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales reported (mil)	206	242	250	260	244	265	279	284	268	308
Sales mean (mil)	208	236	249	278	239	262	276	293	281	296
Surprise	−1.2%	+2.7%	+0.6%	−6.5%	+2.1%	+1.1%	+0.8%	−2.9%	−4.5%	+4.1%
EPS reported	0.10	0.20	0.20	−0.02	0.11	0.16	0.42	1.60	0.02	0.18
EPS mean	0.05	0.18	0.14	0.22	0.11	0.14	0.15	0.14	0.06	0.06
Surprise	+113.7%	+12.0%	+44.8%	−109.3%	−1.3%	+16.7%	+183.8%	+1,067.0%	−67.8%	+213.2%

Peer comparison Biotechnology & Medical Research

Peers in the same industry group, by market capitalization
Company	Market cap	Net debt/EBITDA	Net margin	P/B	FY1 P/E	FY2 P/E	FY1 EV/EBITDA	FY2 EV/EBITDA
ACAD Acadia Pharmaceuticals Inc.	3.5B	−8.20x	36.5%	2.70x	32.9x	22.0x	20.9x	13.6x
ARGX argenx SE	55.0B	−4.75x	31.1%	6.50x	30.7x	23.7x	25.8x	18.8x
INSM Insmed Incorporated	24.0B	0.34x	−210.5%	33.01x	−67.1x	113.9x	−62.4x	142.0x
KYMR Kymera Therapeutics, Inc.	10.9B	2.84x	−794.0%	6.74x	−32.1x	−24.9x	−23.7x	−18.1x
CYTK Cytokinetics, Incorporated	8.6B	0.03x	−891.6%	−49.61x	−10.2x	−13.6x	−12.1x	−16.5x
IONS Ionis Pharmaceuticals, Inc.	6.9B	0.38x	−40.4%	15.53x	−11.5x	−19.1x	−11.2x	−20.1x
Mean		−1.56x	−311.5%	2.48x	−9.6x	17.0x	−10.4x	20.0x
Median		0.19x	−125.5%	6.62x	−10.8x	4.2x	−11.6x	−1.4x

Technical analysis

1M+2.6%
3M−20.9%
1Y−9.8%
3Y−11.0%

Financial statements in millions of USD

Income statement in millions of USD, fiscal years

Income statement, Acadia Pharmaceuticals Inc., fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Total revenue	1,072	958	726	517	484	442
Cost of revenue	89.0	81.8	41.6	10.2	18.0	20.6
Gross profit	983	876	685	507	466	421
Selling, general & administrative expenses	549	488	407	369	396	389
Research & development	329	303	352	362	239	319
Depreciation/amortization	–	–	–	–	1.1	–
Interest expense (income), operating	–	–	–	–	–	–
Unusual expense (income)	0	−147	–	–	–	–
Other operating expenses	0	0	0	0	0	0
Operating income	105	231	−73.4	−224	−170	−287
Net interest income (expense)	31.7	25.5	17.2	6.6	0.6	6.6
Gain (loss) on sale of assets	–	–	–	–	–	–
Other non-operating income (expense)	2.4	1.8	5.1	3.5	2.3	−1.0
Net income before taxes	139	258	−51.0	−213	−168	−281
Provision for taxes	−252	31.6	10.2	2.5	0.4	0.6
Minority interest	–	–	–	–	–	–
Equity in affiliates	–	–	–	–	–	–
U.S. GAAP adjustment	–	–	–	–	–	–
Net income before extraordinary items	391	226	−61.3	−216	−168	−282
Extraordinary items	–	–	–	–	–	–
Net income	391	226	−61.3	−216	−168	−282
EBIT, normalized	105	84.3	−73.4	−224	−170	−287
EBITDA, normalized	117	100	−67.8	−222	−167	−284
Basic EPS, normalized	2.30	0.48	−0.37	−1.34	−1.05	–

Balance sheet in millions of USD, fiscal years

Balance sheet, Acadia Pharmaceuticals Inc., fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Assets
Cash & short-term investments	820	756	439	417	521	632
Receivables	148	105	102	63.1	65.3	50.3
Total inventory	34.7	21.9	35.8	6.6	7.9	9.7
Prepaid expenses	59.5	55.7	39.1	21.4	23.9	25.7
Other current assets	0	0	0	0	0	0
Total current assets	1,062	938	616	508	618	718
Property, plant & equipment	54.9	50.8	56.5	61.6	66.3	56.4
Goodwill	–	–	–	–	–	–
Intangibles	109	120	65.5	–	0	1.1
Long-term investments	–	–	–	–	–	–
Note receivable	–	–	–	–	–	–
Other long-term assets	338	78.9	10.9	18.3	16.0	7.4
Total assets	1,564	1,188	749	588	700	783
Liabilities
Accounts payable	10.9	16.2	17.5	12.7	6.9	8.5
Payable/accrued	–	–	–	–	–	–
Accrued expenses	266	379	237	113	89.2	97.5
Short-term debt	0	0	0	0	0	0
Current portion of long-term debt	–	–	–	–	–	–
Other current liabilities	0	0	0	0	0	0
Total current liabilities	277	395	254	126	96.1	106
Long-term debt	0	0	0	0	0	0
Minority interest	–	–	–	–	–	–
Other liabilities	59.7	60.1	62.9	61.8	63.2	49.6
Total liabilities	337	455	317	187	159	156
Shareholders' equity
Preferred stock	0	0	0	–	–	0
Common stock	0	0	0	0	0	0
Additional paid-in capital	3,039	2,937	2,863	2,771	2,695	2,613
Retained earnings (accumulated deficit)	−1,813	−2,204	−2,431	−2,370	−2,154	−1,986
Treasury stock	–	–	–	–	–	–
Other equity	1.4	0.3	0	−1.0	−0.2	0
Total equity	1,227	733	432	400	541	627
Total liabilities & shareholders' equity	1,564	1,188	749	588	700	783

Cash flow statement in millions of USD, fiscal years

Cash flow statement, Acadia Pharmaceuticals Inc., fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Operating activities
Net income	391	226	−61.3	−216	−168	−282
Depreciation, depletion & amortization	11.8	15.9	5.6	2.0	3.3	2.9
Deferred taxes	−250	–	–	–	–	–
Non-cash items	46.7	−88.8	54.3	61.9	63.7	131
Changes in working capital	−89.8	4.2	18.1	38.0	−24.8	11.0
Cash from operations	110	158	16.7	−114	−126	−136
Investing activities
Capital expenditures	−104	−0.5	−40.0	0	−1.1	−7.6
Other investing cash flows	−199	−30.0	72.0	73.2	−70.0	200
Cash from investing	−303	−30.5	32.0	73.2	−71.1	193
Financing activities
Financing cash flow items	–	–	–	–	–	–
Cash dividends paid	–	–	–	–	–	–
Issuance (retirement) of debt, net	–	–	–	–	–	–
Other financing cash flows	49.9	6.8	25.1	8.2	18.2	81.0
Cash from financing	49.9	6.8	25.1	8.2	18.2	81.0
Foreign exchange effects	0	−0.1	0	0	0	0
Net change in cash	−143	134	73.8	−32.6	−179	137
Free cash flow	6.3	157	−23.3	−114	−127	−144

Disclaimer

The financial data presented in this report is delayed and obtained from sources QDD Research believes to be reliable, including stock exchanges, SEDAR, and EDGAR. However, no representation or warranty is made as to the accuracy, completeness, or timeliness of the information. QDD Research accepts no liability for any errors, omissions, or financial losses arising from the use of this data.

This report is generated using a fully systematic and quantitative approach. All factor scores and the overall quant rating (ranging from D to A+) are derived from algorithmic models and are based solely on objective financial metrics. These scores are intended for informational purposes only and should not be interpreted as investment advice or a recommendation to buy, sell, or hold any securities.

QDD Research is not a registered investment advisor or broker-dealer and does not provide personalized financial advice. The content is not tailored to the specific investment goals, financial situation, or risk profile of any individual investor. We strongly encourage readers to consult with a licensed broker or investment advisor before making any investment decisions based on the information contained in this report.

Live quote provided by TradingView. Report data updated Nov 2, 2026 after market close.